News & Events

*NEW* Collaborative Health Research Projects (CHRP) – Second Webinar Session
Due to the popularity of CIHR’s webinar for their CHRP competition, CIHR will be hosting a second webinar on Monday May 7, 2018 from 1:30 p.m. to 2:30 p.m. EST.

Please register for this webinar here: Register for CHRP Webinar

For the webinar that was held on Monday April 29, 2018, CIHR recorded the session and will make both the audio recording as well as the presentation slides available on their website shortly.

For more information on this funding competition, please visit CIHR’s website

SSHRC Connection Grant Webinars
In May 2018, SSHRC will be holding a series of webinars for applicants and research administrators to provide information and answer questions about upcoming Connection Grants competitions. Webinar participants will have the opportunity to submit written questions via the webinar interface at any point during the presentations. No registration is required, so you can drop in at any time.

Webinar schedule - Connection Grants
English: Wednesday, May 23, 2018, 1:00 to 3:00 p.m. (eastern)
   Link: https://sshrc-crsh.adobeconnect.com/rvgw186apt8h/
French: Thursday, May 24, 2018, 1:00 to 3:00 p.m. (eastern)
   Link: https://sshrc-crsh.adobeconnect.com/r8paf1cdd92d/

To join a webinar:
Click on the link above or copy and paste it into your web browser.
Enter your name in the field provided.
Click “Enter Room” to join the webinar.
Adjust the volume on your computer.

First time attending an Adobe Connect meeting?
Test your connection
Get a quick overview

For technical questions, please contact:
Email: connection@sshrc-crsh.gc.ca
Tel.: 613-943-1007

For questions about the Connection Grant program, please contact Christina Pellegrini, ROADS, at ext. 27207 or pellegrc@mcmaster.ca
### Health Research Grant Competitions

*Programs administered by Health Research Services, unless otherwise indicated. Email: hsresadm@mcmaster.ca*

<table>
<thead>
<tr>
<th>Funding Opportunity (CIHR)</th>
<th>LOI Deadline</th>
<th>Internal HRS Deadline</th>
<th>Sponsor Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CIHR – Operating Grant: Active and Assisted Living Program</strong></td>
<td>May 14</td>
<td>May 28</td>
<td></td>
</tr>
<tr>
<td><strong>NEW</strong> CIHR – Team Grant: ME/CFS Collaborative Project</td>
<td>May 23</td>
<td>Jun 6</td>
<td></td>
</tr>
<tr>
<td>CIHR – Canada Graduate Scholarships – Michael Smith Foreign Study Supplement</td>
<td>May 28</td>
<td>Jun 11</td>
<td></td>
</tr>
<tr>
<td>CIHR – Team Grant: Transnational Cardiovascular Research Projects</td>
<td>Jun 1</td>
<td>Jun 15</td>
<td></td>
</tr>
<tr>
<td>CIHR – Team Grant: E-Rare-3 Joint Transnational Call (2018)</td>
<td>Jun 5</td>
<td>Jun 19</td>
<td></td>
</tr>
<tr>
<td>CIHR Operating Grant: AMR: Point of Care Diagnostics in Human Health – Phase 2</td>
<td>Aug 1</td>
<td>Aug 15</td>
<td></td>
</tr>
<tr>
<td>CIHR – Fellowship: Banting Postdoctoral Fellowships Program</td>
<td>Contact Graduate Studies</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CIHR – Operating Grant: Collaborative Health Research Projects (NSERC Partnered) 2018-2019</strong></td>
<td>May 29</td>
<td>Oct 9 to MILO/Oct 23 to HRS</td>
<td>Oct 30</td>
</tr>
<tr>
<td><strong>E-approval Competition</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Funding Opportunity (Non-CIHR)

<table>
<thead>
<tr>
<th>LOI Deadline</th>
<th>Internal HRS Deadline</th>
<th>Sponsor Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>The Labarge Centre for Mobility in Aging within the McMaster Institute for Research on Aging Catalyst Grant Funding Call for Proposals (Please inform HRS of your intent to apply ASAP)</strong></td>
<td>NOI to HRS ASAP</td>
<td></td>
</tr>
<tr>
<td><strong>The Centre for Aging + Brain Health Innovation (CABHI): Researcher-Clinician Partnership Program (RCP2)</strong></td>
<td>N/A</td>
<td>May 18</td>
</tr>
<tr>
<td><strong>Alex’s Lemonade Stand Foundation: Reach Grants</strong></td>
<td>May 7</td>
<td>May 21</td>
</tr>
<tr>
<td><strong>Alex’s Lemonade Stand Foundation: ‘A’ Awards</strong></td>
<td>May 7</td>
<td>May 21</td>
</tr>
<tr>
<td><strong>Public Works and Government Services Canada: Innovation for Defence Excellence and Security (IDEaS)</strong></td>
<td>May 10</td>
<td>May 24</td>
</tr>
<tr>
<td><strong>Hamilton Scleroderma Group/Scleroderma Society of Ontario (HSG/SSO) Call for Proposals for Peer Reviewed Funding</strong></td>
<td>N/A</td>
<td>May 30</td>
</tr>
<tr>
<td><strong>NEW</strong> Quebec Consortium for Drug Discovery (CQDM): Quantum Leap</td>
<td>May 18</td>
<td>Jun 1</td>
</tr>
<tr>
<td><strong>Hamilton Health Sciences (HHS) Health Professional Investigator Operating Grant Program</strong></td>
<td>N/A</td>
<td>Jun 1</td>
</tr>
<tr>
<td><strong>Urology Care Foundation 2018 Rising Stars in Urology</strong></td>
<td>May 24</td>
<td>May 24</td>
</tr>
<tr>
<td><strong>ALS Canada: ALS Canada Project Grant Program 2018</strong></td>
<td>May 25</td>
<td>Jun 8</td>
</tr>
<tr>
<td><strong>NEW</strong> Mitacs Elevate Spring 2018 Call for Proposals</td>
<td>Jun 13</td>
<td>Jun 27</td>
</tr>
<tr>
<td><strong>Mitacs Globalink Research Internship (GRI)</strong></td>
<td>May 30</td>
<td>Jun 13</td>
</tr>
<tr>
<td><strong>NEW</strong> Bill &amp; Melinda Gates Foundation Grand Challenges - Ending the Pandemic Threat: A Grand Challenge for Universal Influenza Vaccine Development</td>
<td>Jun 8</td>
<td>Jun 22</td>
</tr>
<tr>
<td><strong>NEW</strong> Prostate Cancer Canada: Targeted RFA 2018</td>
<td>May 15</td>
<td>Jun 25</td>
</tr>
<tr>
<td><strong>Brain Tumor Funders’ Collaborative: Immunotherapy for Primary Human Brain Tumors</strong></td>
<td>May 11</td>
<td>Jun 29</td>
</tr>
<tr>
<td><strong>The Royal-Mach-Gaensslen Prize for Mental Health Research</strong></td>
<td>Jul 1</td>
<td>Jul 15</td>
</tr>
<tr>
<td>Funding Opportunity</td>
<td>LOI Deadline</td>
<td>Internal HRS Deadline</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>MRIS Early Researcher Awards Round 14 (Please inform HRS of your intent to apply)</td>
<td>May 29 Draft NOI to HRS</td>
<td>Jun 1 NOI to MRIS</td>
</tr>
<tr>
<td>The Michael J. Fox Foundation: Alpha-Synuclein Biology and Therapies</td>
<td>May 31</td>
<td>Aug 3</td>
</tr>
<tr>
<td>The Michael J. Fox Foundation: Biomarkers of Protein Handling/Autophagy, Exosomes and Lipids</td>
<td>May 31</td>
<td>Aug 3</td>
</tr>
<tr>
<td>The Michael J. Fox Foundation: GBA Biology and Therapies</td>
<td>May 31</td>
<td>Aug 3</td>
</tr>
<tr>
<td>The Michael J. Fox Foundation: Non-Pharmacological Interventions for Gait and Balance Disturbances</td>
<td>May 31</td>
<td>Aug 3</td>
</tr>
<tr>
<td>Health Quality Ontario: Adopting Research to Improve Care (ARTIC) Program</td>
<td>May 25</td>
<td>Sep 10</td>
</tr>
<tr>
<td>McMaster University, McMaster Institute for Research on Aging (MIRA), Labarge Centre for Mobility in Aging (LCMA): Matching Funds for Research Opportunities</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>MITACS Accelerate Fellowship</td>
<td></td>
<td>Ongoing MILO</td>
</tr>
<tr>
<td>Weston Brain Institute: Early Phase Clinical Trials: Canada</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>Simons Foundation, Simons Foundation Autism Research Initiative (SFARI): SFARI Explorer Award</td>
<td></td>
<td>Ongoing</td>
</tr>
<tr>
<td>OCE Voucher for Innovation and Productivity (VIP I) Program</td>
<td></td>
<td>Ongoing MILO</td>
</tr>
<tr>
<td>OCE Voucher for Innovation and Productivity II (VIP II) Program</td>
<td></td>
<td>Ongoing MILO</td>
</tr>
<tr>
<td>TalentEdge Internship Program (TIP)</td>
<td></td>
<td>Ongoing MILO</td>
</tr>
<tr>
<td>TalentEdge Fellowship Program</td>
<td></td>
<td>Ongoing MILO</td>
</tr>
<tr>
<td>MITACS Accelerate Program</td>
<td></td>
<td>Ongoing MILO</td>
</tr>
<tr>
<td>MITACS Globalink Partnership Award</td>
<td></td>
<td>Ongoing MILO</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Funding Opportunity (DoD)</th>
<th>LOI Deadline</th>
<th>Internal HRS Deadline</th>
<th>Sponsor Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Department of Defense Breast Cancer Research Program (BCRP) Funding Opportunities for Fiscal Year 2018</td>
<td>May 15/16</td>
<td>May 23/Jul 31</td>
<td>May 30/Aug 14</td>
</tr>
<tr>
<td>Department of Defense Peer Reviewed Medical Research Program (PRMRP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jun 12/14/19</td>
<td>Jun 21/Sep 6</td>
<td>Jun 28/Sep 20</td>
</tr>
<tr>
<td>Department of Defense Amyotrophic Lateral Sclerosis Research Program (ALS RP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jun 22</td>
<td>Sep 27</td>
<td>Oct 11</td>
</tr>
<tr>
<td>Department of Defense Bone Marrow Failure Research Program (BMFRP) Funding Opportunities for Fiscal Year 2018</td>
<td>Jul 16</td>
<td>Oct 18</td>
<td>Nov 1</td>
</tr>
</tbody>
</table>
CIHR – Operating Grant: Active and Assisted Living Program
By funding the development of packages integrating different solutions, the AAL Programme aims to create evidence of improved quality of life, of perceived added value by end-users, of usefulness and of effectiveness of the solutions, as well as of their reliability, security and financial viability, including positive business cases for potential payers.
Impact will be assessed via:
- Expected impact on quality of life
- Expected impact on the market
For a complete description of these expectations, please refer to the Active and Assisted Living website.

Funding Details: The total amount available for a Canadian-based applicant for this funding opportunity is $353,000 (CAD), enough to fund approximately one (1) grant. This amount may increase if additional funding partners participate. The maximum amount per grant is $117,666 (CAD) per year for one (1) grant for a maximum of three (3) years

Additional Details
Internal HRS Deadline: May 14, 2018
Sponsor Deadline: May 28, 2018

CIHR – Team Grant: ME/CFS Collaborative Project
The objective of this grant is to create an environment where Canadian researchers collaborating with NIH’s CRCs and DMCC can combine their relative strengths to advance our understanding of ME/CFS, and to define the cause(s) of and discover improved treatments for ME/CFS through:
- Identifying and establishing novel connections across Canada, bringing together a multidisciplinary and interdisciplinary cohort of technical and scientific experts for research collaboration and dialogue in the area of ME/CFS.
- Developing and strengthening ME/CFS research capacity by establishing innovative approaches to catalyze current researchers and training opportunities for the next generation of ME/CFS researchers.
- Developing and providing health research leadership across Canada and beyond, with innovative approaches to promote current and emerging directions and priorities in ME/CFS, including the facilitation and support of effective translation, dissemination and application of new knowledge generated through the appropriate use of research evidence.
In addition, the objective for the supplementary funding available to the Canadian team is to generate new scientific knowledge to advance our understanding of the vascular instability and/or sleep disturbances experienced by people with ME/CFS.

Funding Details: The total amount available from CIHR for this funding opportunity is $1,775,000, enough to fund one (1) team. This amount may increase if additional funding partners participate.
- The maximum amount for the grant is $280,000 per year for up to five (5) years, for a total of up to $1.4 million, for the participation of one team in the ME/CFS Initiative Collaborative Project.
- A supplementary amount of $75,000 per year for up to five (5) years, for a total of $375,000, is available to the above team for a project that also addresses vascular instability and/or sleep disturbances experienced by people with ME/CFS.

Additional Details
Internal HRS Deadline: May 23, 2018
Sponsor Deadline: June 6, 2018

CIHR – Canada Graduate Scholarships – Michael Smith Foreign Study Supplement
The specific objectives of this funding opportunity are:
- to support high-caliber Canadian graduate students in building global linkages and international networks through the pursuit of exceptional research experiences abroad; and
- to strengthen the potential for collaboration between Canadian institutions and other research institutions outside of Canada.

Funding Details: The total amount available for this funding opportunity is $270,000, enough to fund approximately 45 awards. The maximum amount per award is $6,000 for a defined research study period outside of Canada for a minimum of two months to a maximum of six months.

Additional Details
Internal HRS Deadline: May 28, 2018
Sponsor Deadline: June 11, 2018
CIHR – Team Grant: Transnational Cardiovascular Research Projects

The ERA-CVD JTC2018: Transnational Cardiovascular Research Projects driven by Early Career Scientists is expected to:

- foster transnational cooperation of European countries and beyond, and to coordinate research efforts and funding programs of the ERA-CVD partner countries with Canada
- promote co-operation and interchange between Early Career Scientists and thus enable international collaboration and new consortia establishment in cardiovascular research,
- enable capacity building and empowering of Early Career Scientists by providing opportunity to independently develop and perform highly innovative research projects,
- add value in funding the collaboration over individual projects by sharing of resources (e.g., models, databases, diagnosis etc.), harmonization of data, sharing of specific know-how and/or innovative technologies, etc.

**Funding Details:** The total amount available for Canadian applications is Can$ 585,000, which is enough to fund approximately two (2) grants. This amount may increase if additional funding partners participate. The maximum amount available per grant to Canadian participants in transnational consortia is Can$ 97,500 per year for up to three (3) years for a total of Can$ 292,500, per grant.

**Additional Details**

Internal HRS Deadline: June 1, 2018
Sponsor Deadline: June 15, 2018

CIHR Team Grant: E-Rare-3 Joint Transnational Call (2018)

There are at least 7,000 distinct rare diseases, the great majority being of genetic origin. Although individually rare, taken together rare diseases affect at least 26-30 million people in Europe alone. Moreover, they represent a major issue in health care: a large number of these diseases have an early or very early onset and/or lead to a significant decrease of life expectancy. Moreover, most of them cause chronic illnesses with a large impact on quality of life and the health care system. Therefore, research on rare diseases is needed to provide knowledge for prevention, diagnosis and better care of patients. Yet, research is hampered by lack of resources at several levels:

1. Few scientists work on any given specific disease,
2. There are few patients per disease and they are scattered over large geographic areas, causing difficulties to assemble the necessary cohorts,
3. Existing databases and bio-material collections are usually local, small, and not accessible or standardised,
4. The complex clinical phenotypes of these diseases require interdisciplinary cooperation to improve research and treatment.

The specificities of rare diseases - limited number of patients, scarcity of relevant knowledge and expertise, and fragmentation of research - single them out as a distinctive domain of very high European added-value. Rare diseases are therefore a prime example of a research area that necessitates collaboration/coordination on a transnational scale. In this context, the ERA-NET “E-Rare” for research programs on rare diseases has been extended to a third phase “E-Rare-3” (2014-2019) to further help in coordinating the research efforts of European, Associated and non-European countries in the field of rare diseases and implement the objectives of the International Rare Disease Research Consortium (IRDiRC). CIHR is pleased to be partnering with the Fonds de recherche du Québec – Santé (FRQS) once again in the context of this ERA-Net.

**Funding Details:** The total amount available for this funding opportunity is $2,000,000, enough to fund 5-6 grants. This amount may increase if additional funding partners participate. The maximum amount per grant is $125,000 per year for up to 3 years for a total of $375,000 per grant. Of this $2,000,000, $500,000 is available to fund applications relevant to the mandate of the Fonds de recherche du Québec – Santé FRQS.

**Additional Details**

Internal HRS Deadline: June 5, 2018
Sponsor Deadline: June 19, 2018

CIHR Operating Grant: AMR: Point of Care Diagnostics in Human Health – Phase 2

The Antimicrobial Resistance: Point of Care Diagnostics in Human Health Phase 2 funding opportunity is expected to:

- Improve rational use of antibiotics and clinical management by increasing availability, timeliness, and uptake of clinically relevant point-of-care diagnostic tools in AMR.
- Integrate evidence-informed therapeutic approaches and prevention interventions into health care practice and policy.
• Determine commercial viability and show direct clinical applicability of a technology or tool that has passed the preliminary design development phase.

• Enhance capacity to conduct international, intersectoral and interdisciplinary AMR research through collaboration and training of researchers and health care professionals.

Funding Details: The total amount available for this funding opportunity is $2,025,000, enough to fund approximately 3 grants. The maximum amount per grant is $225,000 per year for up to 3 years for a total of $675,000 per grant.

Additional Details
Internal HRS Deadline: August 1, 2018
Sponsor Deadline: August 15, 2018

The Clinical Trials Network in HIV/AIDS is expected to:

• Develop and implement a strategic, outcome-oriented clinical trials research agenda to ensure alignment with current and emerging priorities in HIV, hepatitis C and/or other STBBIs and related health conditions;

• Sustain a high quality national infrastructure (including methodological expertise, data management and analysis, research support staff and regulatory expertise) to enable Canadian researchers to collaboratively and efficiently conduct innovative and excellent clinical trials and related research across Canada and internationally;

• Accelerate the translation and uptake of new knowledge into clinical applications and guidelines for patient care to support the adoption of best practices by clinicians, caregivers and patients;

• Engage stakeholders and partners (including people living with HIV, hepatitis C and/or other STBBIs; community organizations; Indigenous peoples; clinicians; policy makers; and relevant national networks) in CTN activities and governance committees to ensure their active and meaningful involvement;

• Strengthen Canadian research capacity to conduct and apply clinical research through training and mentoring initiatives; and

• Strengthen the networking and partnership strategies and secure additional funding to maximize the impact and outcomes of the Network and work toward sustainability.

Funding Details: The total amount available for this funding opportunity is $22,850,000, enough to fund 1 grant. This amount may increase if additional funding partners participate. The maximum amount is $4,570,000 per year for up to 5 years.

Additional Details
Internal HRS Deadline: August 28, 2018
Sponsor Deadline: September 11, 2018

CIHR – Fellowship: Banting Postdoctoral Fellowships Program
The fellowships will be known as the Banting Postdoctoral Fellowships, in memory of Sir Frederick Banting, the Canadian physician, researcher, Nobel laureate and war hero who, together with his assistant Dr. Charles Best, is credited with the discovery of insulin. The Banting Postdoctoral Fellowships program provides funding to the very best postdoctoral applicants, both nationally and internationally, who will positively contribute to the country's economic, social and research-based growth. The program is jointly administered by Canada’s three federal granting agencies: the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council (NSERC) and the Social Sciences and Humanities Research Council (SSHRC). CIHR has been designated as the operational lead for the implementation of the program.

Funding Details: The total amount available for this funding opportunity is $9,800,000, enough to fund approximately 70 awards. The maximum amount per award is $70,000 (taxable) per year, for up to two (2) years and a total of $140,000 per award. The funding is not renewable.

Additional Details
Contact Correen Smith in Graduate Studies to Apply
Sponsor Deadline: September 19, 2018

CIHR – Operating Grant: Collaborative Health Research Projects (NSERC Partnered) 2018-2019
In the context of improved health for Canadians, the objectives of the Collaborative Health Research Projects (CHRPRP) initiative are to:

• Translate research results to knowledge/technology users (KTUs) and other stakeholders;
• Encourage the natural sciences and/or engineering and health research communities to collaborate and integrate their expertise;
• Advance interdisciplinary research leading to knowledge and technologies;
• Benefit Canada by improving the Canadian healthcare system and/or services;
• Lead to economic opportunities in Canada (where appropriate); and
• Provide training opportunities in collaborative and interdisciplinary research of relevance to health, while preparing them for employment opportunities in the private, public or not for profit sectors.

**Funding Details:** The total amount available for this funding opportunity is $24.875 million. The maximum duration of support for any one grant is three years.

**Additional Details**
- **LOI Deadline:** May 29, 2018
- **Internal HRS Deadline:** October 23, 2018 E-approval Competition
- **Sponsor Deadline:** October 30, 2018

---

**The Labarge Centre for Mobility in Aging within the McMaster Institute for Research on Aging**

**Catalyst Grant Funding Call for Proposals**

**Catalyst Grants**
Catalyst grants offer the opportunity to conduct collaborative and interdisciplinary research focused on mobility in aging. These grants are intended to stimulate new collaborations and allow researchers to collect preliminary data to support future proposals for full-scale studies. Catalyst grants are valued at up to $40,000 (over one year) to conduct feasibility/pilot studies or scaling of interventions. These grants require matching funds of at least $5,000 (can include up to $2,500 of in-kind contributions) from alternate sources to support the project.

**Requirements**
Funds will be allocated for up to six catalyst grants in 2018. Each Faculty is asked to submit one proposal to MIRA through the Associate Dean (Research). Submissions should include researchers from at least three different McMaster Faculties as meaningful contributors to the project. Any researcher who was identified as Principal Investigator (PI) in a 2017 Catalyst Grant may not also be the PI in the current year; however, he/she may participate as a co-investigator.

**Funding Details:** Catalyst grants are valued at up to $40,000 over one year.

**NOI to HRS Deadline:** ASAP
Only one application can be submitted by each faculty under this call. Please contact Tracy Arabski, Director, HRS, at arabski@mcmaster.ca or x22515 with your intent to apply ASAP

---

**The Centre for Aging + Brain Health Innovation (CABHI): Researcher-Clinician Partnership Program (RCP2)**

**The Centre for Aging + Brain Health Innovation (CABHI):** CABHI is a solution accelerator for the aging and brain health sector. Our driving purpose is to facilitate the improvement of healthcare outcomes for older adults by fostering ground-breaking collaborations among leading global innovators and seniors’ care organizations in North America and around the world.

**Program Objective:** This program is designed to enhance the effectiveness of connecting point of care clinicians in the senior care sector with university-based researchers to collaboratively design, test and validate innovative products, services or health practice in the aging and brain health sector. Through RCP2, CABHI will provide up to $500,000 in funding per project to support those project costs directly associated with the trial testing of an innovative solution at an advanced stage of development within an aging population group in North America.

**Challenge Sets:** CABHI will direct funding at innovations addressing challenge sets listed below:

- **Aging in place:** solutions that enable older adults with dementia to maximize their choice, independence and quality of life to enable aging in the most appropriate setting
- **Care support:** solutions that support caregivers (formal and informal) in providing care to older adults with dementia
- **Care coordination and navigation:** solutions that help older adults, caregivers and healthcare providers coordinate care and transitions for older adults with dementia
• **Cognitive health**: solutions that focus on health promotion, prevention, early diagnostics, and slow the progression of cognitive impairment for aging adults

**Eligibility**: Teams may include researchers, clinicians, educators, industry partners and/or end-users located worldwide. However, each team must include at least one clinician and one researcher; one of whom must be identified as the project’s Principal Investigator, who must be employed by an institution that is a Canada Revenue Agency “qualified donee” located in Canada.

**Funding Details**: Through RCP2, CABHI will provide up to $500,000 in funding per project. Timeline not to exceed 15 months.

**Additional Details**
**Sponsor Deadline**: May 18, 2018
*If you are interested in submitting an application, please contact the McMaster Industry Liaison Office (MILO): Carmen Carrasquilla at carrasc@mcmaster.ca Ext. 21088*

**Alex’s Lemonade Stand Foundation: Reach Grants**
The purpose of the Reach Grant is to advance ALSF’s mission to find cures and better treatments for childhood cancers by providing support to move hypothesis-driven research into the clinic. Significant barriers exist that impede the translation of innovative and important ideas to the clinic. The Reach Grant seeks to remove one of these barriers by providing support for important preclinical projects that are necessary to move a study from the pre-clinical arena into a clinical trial. Thus, the goal of this award is to support selected late translational studies. Preference will be given to those research projects which, if funded, will likely result in the initiation of a clinical trial two to three years from the start of the project.

**Funding Details**: The award is up to $125,000 annually for two years.

**Additional Details**
**Internal HRS Deadline**: May 7, 2018
**Sponsor Deadline**: May 21, 2018

**Alex’s Lemonade Stand Foundation: ‘A’ Awards**
ALSF is excited to commit substantial resources to early independent career scientists that want to establish a career in pediatric oncology research. An original project that is not currently funded should be proposed. Demonstration of a future commitment to pediatric cancer research is expected, as well as institutional support for the career development of the investigator. These are key components of a successful application. **Important**: There are new eligibility criteria and other changes to this grant category.

**Funding Details**: Initial Awards are for $800,000 over 4 years (no more than $200,000 in any given year)

**Additional Details**
**Internal HRS Deadline**: May 7, 2018
**Sponsor Deadline**: May 21, 2018

**Public Works and Government Services Canada: Innovation for Defence Excellence and Security (IDEaS)**
Are you an innovator? Regardless if you are working from your home, an academic in a university lab or a scientist in a small or a major corporation, the Innovation for Defence, Excellence and Security (IDEaS) program is looking for your solutions to help resolve defence and security challenges. This is your opportunity to showcase your innovative ideas. In April 2018, IDEaS launched its inaugural public Call for Proposals (CFP). This Competitive Projects (CFP) is now open with 16 defence and security challenges in many domains. Check the challenges today and see where your ideas may be part of the solution.

**Funding Details**: Maximum $200,000 for a maximum of 6 months

**Additional Details**
**Internal HRS Deadline**: May 10, 2018
**Sponsor Deadline**: May 24, 2018
*To apply, contact, Sarah McNiven-Scott, Senior Grants Advisor, Major Projects, HRS, at mcnivesb@mcmaster.ca or ext. 22871*
**Hamilton Scleroderma Group/Scleroderma Society of Ontario (HSG/SSO) Call for Proposals for Peer Reviewed Funding**

The aim is to foster research in systemic sclerosis, and to “seed fund” projects to gather suitable preliminary data to be competitive in larger grants. Faculty at McMaster University are eligible to apply. The research project must be of direct relevance to systemic sclerosis, and ideally will generate pilot data with which to support an application for funding from other sources.

**Funding Details:** $25,000 maximum per scholarship for one year

**Internal HRS Deadline:** N/A

**Sponsor Deadline:** May 30, 2018

*For questions regarding the award or the submission process, contact Ms. Andrea Gardner at gardnera@stjoes.ca*

---

**Quebec Consortium for Drug Discovery (CQDM): Quantum Leap**

The Quantum Leap program is intended to support outstanding translational research projects implementing state-of-the-art technologies with very high potential impact in key areas of unmet needs within the biopharmaceutical industry. It is expected that the funded technologies should provide valuable opportunities for future collaborations and/or investment from key partners on a global scale. This program is aimed at developing highly innovative technologies, platforms or tools with strong preliminary data showcasing high potential to drastically improve, facilitate and accelerate the process of discovery and development of drugs that prevent, treat or cure diseases in all major indications pursued by the biopharmaceutical industry.

**Funding Details:** CQDM will consider applications with total budget ranging from $500,000 to $2,000,000. In exceptional cases with outstanding projects, CQDM could consider budget above $2,000,000. Duration will be for projects from 1-3 years.

---

**Hamilton Health Sciences (HHS) Health Professional Investigator Operating Grant Program**

The Health Professional Investigator (HPI) Operating Grant provides project funding to principal investigators (PI) who are HHS-employed healthcare professionals. Inter-professional teams, which include physicians, are encouraged, but physicians are not eligible to apply as lead PI for this grant. The HPI Operating Grant is for research initiatives directly relevant to the clinical mission and priorities/strategic plan of HHS (Patients, People, Sustainability, Innovation and Learning). The grant objective is to provide support for pilot studies or research projects that have the potential to lead to larger projects and the possibility of external funding. The HPI Operating Grant offers an opportunity to foster and support a culture of inquiry for novice to novice to mid-career investigators under the mentorship of experienced researchers.

**Funding Details:** up to $15,000 per grant, three grants available for a one-year term.

---

**Urology Care Foundation 2018 Rising Stars in Urology**

The Rising Stars in Urology Research Award program provides up to five years of supplemental salary support to urologists who have successfully competed for career development awards from the National Institutes of Health (NIH) or other major funding organizations. These awards ensure that the salary compensation for those committed to careers in urologic research remain competitive with that of their clinical urology peers. The program encourages recipients to contribute to urology as both surgical specialists and scientists investigating causes, prevention, treatment and cures that will improve patients’ lives.

**Funding Details:** Though the award has a maximum duration of five years, the period of salary supplementation will be commensurate with the period of performance of the existing career development award. Funding starts at $28,000 in year 1 and increases each award year based on the following schedule: year 2, $33,000; year 3, $40,000; year 4, $46,000; and year 5, $52,000.

---

*LOI Deadline: May 24, 2018*
ALS Canada: ALS Canada Project Grant Program 2018

The 2018 Project Grant Program encompasses applications previously designated for Discovery, Bridge or Clinical Management Grant competitions. The purpose of the program is to invest in the best possible projects that are i) novel research approaches, supported by sound rationale and a feasible experimental plan, but not necessarily preliminary data, ii) part of an ongoing ALS research program, and aimed toward the vision of ALS Canada, which is “A future without ALS” or iii) research focused on avenues to maximize function, minimize disability and optimize quality of life through symptom management, and support to families and persons or families living with ALS. Examples include, but are not limited to, management of secretions and cramps, psychological interventions to address mental health issues, nutritional interventions, respiratory care, engineering applications to reduce physical limitations, and programs to address the needs of caregivers.

Funding Details: Up to $1,000,000 available (anticipated 8 x $125,000 grants for use over 1 or 2 years)

Mitacs Elevate: Spring 2018 Call for Proposals

Mitacs Elevate is a postdoctoral fellowship with a customized research management training component. Fellows address complex challenges through:

- An exclusive research management curriculum for postdoctoral fellows in any discipline
- A minimum one-year research project (normally two years in duration) with a partner organization in need of high-level expertise
- A Partner Organization Business Case, developed to outline project objectives, risks, and stakeholder success criteria, and ensure project value

Elevate fellows progress through the program in a cohort, giving them cross-disciplinary networking and peer-learning opportunities they might not have otherwise in their careers.

Funding Details: Elevate fellows receive $55,000 minimum annual stipend/salary (for fellowships awarded after April 1, 2018) and training curriculum valued at $7,500 per year. Maximum 2 years.

Mitacs Globalink Research Internship (GRI)

The Mitacs Globalink Research Internship is a competitive initiative for international undergraduates from Australia, Brazil, China, France, India, Germany, Mexico, Saudi Arabia, Tunisia, and Ukraine. From May to October of each year, top-ranked applicants participate in a 12-week research internship under the supervision of Canadian university faculty members in a variety of academic disciplines, from science, engineering and mathematics to the humanities and social sciences.

- April to June 2018: Professors submit research projects to Mitacs. All accepted projects are made available to student applicants in an online database. Professor project proposals are due June 13, 2018, by 1 p.m. PT, for 2019 Globalink Research Internships.
- July to September 2018: International students submit applications and select research projects from the online database.
- October to December 2018: Mitacs provides professors with proposed student candidates for their project, including application details, statement of research interests, CV, transcripts, and references. Professors are then encouraged to contact or interview the suggested students and provide feedback to Mitacs.
- January to April 2019: Professors and their accepted student(s) arrange pre-internship details (e.g., reading to be completed beforehand) while Mitacs oversees logistics and coordinates with university administrative offices.
- May to September 2019: Globalink Research Interns arrive in Canada and work with supervising professors for 12 weeks on their research project.
Bill & Melinda Gates Foundation Grand Challenges - Ending the Pandemic Threat: A Grand Challenge for Universal Influenza Vaccine Development

The objective of this funding opportunity is to find a game changing, universal solution to all these challenges, the Bill & Melinda Gates Foundation and the Page Family are launching the “Universal Influenza Vaccine Development Grand Challenge” during the centenary year of the 1918 flu pandemic. The goal of this Grand Challenge is to identify novel, transformative concepts that will lead to development of universal influenza vaccines offering protection from morbidity and mortality caused by all subtypes of circulating and emerging (drifted and shifted) Influenza A subtype viruses and Influenza B lineage viruses for at least three to five years. It is envisaged that such a universal influenza vaccine would address the threat from both seasonal and pandemic influenza, thus alleviating the need for annual seasonal influenza vaccination campaigns, averting significant global morbidity and mortality, and better preparing the world for the next influenza pandemic.

Funding Details: This request for proposals intends to fund pilot awards of up to USD $2 million over 2 years

Prostate Cancer Canada: Targeted RFA 2018

This request for applications (RFA) solicits proposals from groups developing and validating methods to specifically and accurately predict treatment response and/or patient outcome using an appropriate assay. The end goal is clinical validation of the approach and more accurate and personalized selection of treatments for patients with prostate cancer. It is expected that a multidisciplinary approach will be required and each Movember TAG application may consist of independent investigators based in multiple institutions. PCC also strongly encourages, wherever possible, that applications would access and use existing banked clinical specimens. PCC will only consider projects that are completely focused on prostate cancer.

Funding Details: up to $1.5M over 3 years

Brain Tumor Funders’ Collaborative: Immunotherapy for Primary Human Brain Tumors

The Brain Tumor Funders’ Collaborative invites responses to its current funding initiative focused on understanding the complex dynamics among the constituents comprising the human neuro-immune system, the heterogeneity of the primary brain tumor, and the brain environment. The BTFC is requesting proposals on the role of the neuro-immune system in the origin and progression of the immune responses in primary human brain tumors with the hope of developing immunotherapies for treatment of these tumors in patients. The initial response to the RFP requires pre-proposals describing studies on the complex roles of immune responses in the context of primary brain tumors in pediatric and/or adult human patients.

Funding Details: maximum of $250,000 for each project per year for three years

The Royal-Mach-Gaensslen Prize for Mental Health Research

The Royal-Mach-Gaensslen Prize for Mental Health Research was established in 2015 and is awarded annually to recognize and support rising star Canadian research scientists with a focus in the area of mental health. This annual national Prize provides funding to outstanding rising star researchers who are affiliated with a Canadian academic or clinical research institution in the field of mental health.
mental health, to encourage them to continue to pursue their research interests in Canada. It recognizes those with a demonstrated track record in research with excellence in scientific rigor, innovative thinking, imagination and originality and a clear ability to work in partnership with other disciplines and/or research teams external to the institution with which they are affiliated. This competition will occur once a year for 10 years.

**Funding Details:** $100,000 for one year

**Additional Details**
*Internal HRS Deadline: July 1, 2018*
*Sponsor Deadline: July 15, 2018*

**MRIS Early Researcher Awards Round 14**
The Ontario Ministry of Research, Innovation and Science (MRIS) has issued the call for proposals for Round 14 of the Early Researcher Awards (ERA) competition. The ERA program helps promising, recently-appointed Ontario researchers build their research teams of undergraduates, graduate students, post-doctoral fellows, research assistants, associates and technicians. The ERA program encourages applications from all disciplines. Proposals will be evaluated on the excellence of the researcher (40%), the quality of the research (30%), the development of research talent (20%), and the strategic value for Ontario (10%).

**Matching funds are required for this program.** Also, to be competitive, applicants must have a strong history of peer-reviewed funding and must be able to demonstrate academic independence from previous supervisors and the benefits of their proposed research to Ontario. Therefore, it is advised that you meet with your Department Chair and Associate Dean Research to review your CV and secure matching funds.

**Funding Details:** Each award is a maximum of $100,000 over five years. These funds may be used for salaries, benefits and research-related travel and expenses for undergraduates, graduate students, post-doctoral fellows, research assistants, associates and technicians. In addition, up to $40,000 will be provided by the Ministry to the institution for indirect costs. The award of $100,000 for direct costs must be matched by an additional $50,000 in cash from the researcher’s institution and/or a private or public-sector partner.

**Additional Details**
*NOI Due to HRS: May 29, 2018*
*NOI Due to MRIS: June 1, 2018*
*Internal HRS Deadline: July 25, 2018*
*Sponsor Deadline: August 7, 2018*

*If you have any questions regarding the ERA program, please contact Tracy Arbski, Director, HRS, at arabski@mcmaster.ca or extension 22515*

**The Michael J. Fox Foundation: Alpha-Synuclein Biology and Therapies**
The Michael J. Fox Foundation will award one-to-two-year grants for alpha-synuclein research to advance understanding of alpha-synuclein biology and accelerate therapeutic approaches. This program seeks proposals for research studying:

- The role of alpha-synuclein and modified forms in health and disease
- The relationship between alpha-synuclein structure and physiological functions
- Novel therapeutic approaches targeting intracellular alpha-synuclein or related pathways

A pathological hallmark of Parkinson’s and other neurodegenerative disorders, alpha-synuclein accumulation into Lewy bodies is thought to play a major role in the onset and/or progression of disease. Clinical trials are ongoing for several potential treatments targeting extracellular alpha-synuclein. MJFF will support projects aimed at altering intracellular alpha-synuclein in order to broaden the scope of therapeutic approaches.

**Funding Details:**
- Biological Pathways & Novel Targets: 1-2 year grants, up to $150,000
- Therapeutic Development: 1-2 year grants, up to $500,000

**Additional Details**
*LOI Deadline: May 31, 2018*
*Internal HRS Deadline: August 3, 2018*
**The Michael J. Fox Foundation: Biomarkers of Protein Handling/Autophagy, Exosomes and Lipids**

The Michael J. Fox Foundation will award one-to-two-year grants to advance biomarker assays in three highly relevant Parkinson’s disease (PD) biology research areas. Investigators working on assay development, optimization of existing assays and clinical sample assessment are encouraged to apply. This program seeks proposals for research studying biomarkers of:

- Protein handling/autophagy pathways
- Exosomes of neuronal origin (including assays to measure proteins, nucleic acids, lipids or metabolites)
- Lipids (including absolute and relative quantification and identification of lipid series)

To date, research into protein handling, exosomes, and lipidomics has mainly focused on dissecting the molecular pathways, understanding biological dysfunction and elucidating associated pathophysiology. Scientists have observed differences in these cellular processes in cellular and animal models, as well as some data in people with Parkinson’s. The next step in translating these important biological targets for clinical intervention is to develop, validate and assess key markers in human biofluids/biospecimens.

**Funding Details:** Funding is commensurable with the study goals.

**Additional Details**

**LOI Deadline:** May 31, 2018

**Internal HRS Deadline:** August 3, 2018

**Sponsor Deadline:** August 20, 2018 (by invite only)

---

**The Michael J. Fox Foundation: GBA Biology and Therapies**

The Michael J. Fox Foundation and The Silverstein Foundation for Parkinson’s with GBA will award one-to-two-year grants for GBA research to advance understanding of GBA biology and accelerate therapeutic approaches. This program seeks proposals for research studying:

- How GBA mutations lead to PD
- Mechanisms underlying GCase dysfunction in the absence of GBA mutations
- Novel therapeutic interventions to prevent pathogenic mechanisms triggered by GCase-pathway dysfunction

Mutations in the glucocerebrosidase (GBA) gene are one of the most common risk factors for Parkinson’s disease. GBA encodes a lysosomal enzyme, beta-glucocerebrosidase (GCase). Reduced GCase activity is associated with GBA mutations and has been reported in idiopathic PD, suggesting a more general role for GCase pathway dysfunction in Parkinson’s. The exact cellular mechanism by which GCase deficits contribute to the pathogenesis of PD remains unclear, warranting further investigation.

**Funding Details:**

- **Biological Pathways & Novel Targets:** 1-2 year grants, up to $150,000
- **Therapeutic Development:** 1-2 year grants, up to $500,000

**Additional Details**

**LOI Deadline:** May 31, 2018

**Internal HRS Deadline:** August 3, 2018

**Sponsor Deadline:** August 20, 2018 (by invite only)

---

**The Michael J. Fox Foundation: Non-Pharmacological Interventions for Gait and Balance Disturbances**

The Michael J. Fox Foundation will award one-to-two-year grants to test non-pharmacological interventions for the treatment of gait and balance disturbances in people with Parkinson’s disease (PD). We are particularly interested in proof-of-concept, validation and data-analysis projects. This program seeks proposals for research studying the therapeutic benefit of:

- Assistive devices (e.g., back or leg braces)
- Novel technologies (e.g., laser or wearable devices)
- Rehabilitative therapy programs (e.g., occupational or physical therapy)

Gait and balance disturbances in PD can lead to falls, injury, disability and diminished quality of life. While existing dopamine therapies offer therapeutic benefit in treating motor dysfunction in PD, pharmacological-based interventions may not fully ameliorate challenges in gait and balance.
MJFF will prioritize projects that aim to demonstrate proof of concept of methods, feasibility of use and reasonable merit to help gait and balance disturbance in PD. Promising novel technologies must have at least a prototype available to test for proof of concept. Projects also may aim to analyze preliminary existing data around devices or programs. At the end of the proposed project period, technology or approach has the potential to be quickly integrated into patient care.

Please note: This program is not appropriate for technology development, cognitive-based interventions (e.g., cognitive behavioral therapy) or exercise intervention programs.

**Funding Details:** 1-2 year grants up to $500,000

**Additional Details**
**LOI Deadline:** May 31, 2018  
**Internal HRS Deadline:** August 3, 2018  
**Sponsor Deadline:** August 20, 2018 (by invite only)

---

**Health Quality Ontario: Adopting Research to Improve Care (ARTIC) Program**

The Adopting Research to Improve Care (ARTIC) Program is a proven model for accelerating the implementation of research evidence into broader practice, contributing to improving the quality of care across Ontario. It is a continuing partnership co-led by Health Quality Ontario (HQO) and the Council of Academic Hospitals of Ontario (CAHO) and brought to life through the Program’s engagement with a wide array of system partners. Too often, research evidence that improves the quality of care are successfully implemented and adopted into practice in one organization, yet this knowledge is never spread to other 5 organizations. Effective evidence implementation and change management require an investment of time, knowledge, expertise, and funding. The ARTIC Program is designed to support and accelerate the implementation and spread of proven clinical interventions or practice changes by strengthening enablers and addressing barriers to support adoption and spread of research evidence across organizations to achieve optimal impact and outcomes.

**Funding Details:** For 2018/2019 fiscal year, The ARTIC Program will be funding at least one spread project over a 24-month period. The maximum funding available for projects selected in this call for proposals is $1,000,000.

**Additional Details**
**LOI Deadline:** May 25, 2018  
**Internal HRS Deadline:** September 10, 2018  
**Sponsor Deadline:** September 24, 2018

---

**McMaster University, McMaster Institute for Research on Aging (MIRA), Labarge Centre for Mobility in Aging (LCMA): Matching Funds for Research Opportunities**

The McMaster Institute for Research on Aging (MIRA) aims to optimize the health and longevity of the aging population through leading-edge research, education and stakeholder collaborations. The institute intends to amplify McMaster’s strength in aging-focused research through stimulating new partnerships, facilitating access to research funding, raising the profile of McMaster’s research platforms, and building capacity among students and faculty members. In order to improve the positioning of McMaster’s researchers in external funding competition, MIRA and the Labarge Centre for Mobility in Aging (LCMA) have allocated funding that could be used to match or leverage external funds. This process is intended to be used for requests related to externally funded, peer-reviewed grant competitions that require a matching component.

**Funding Details:** maximum $100,000 (total cash and/or in-kind) non-renewable funding anticipated support 1-2 projects per year

**Additional Details**  
**Sponsor Deadline:** Ongoing

---

**MITACS Accelerate Fellowship**

The Mitacs Accelerate Fellowship provides a long-term funding and internship option for master’s and PhD students. Recipients can also access professional development training that helps them ensure project success and gain in-demand career skills. Interested applicants can apply for the Accelerate Fellowship at any time. All other Accelerate program guidelines apply.

**Funding Details:**
• **Master’s students** - $40,000 total research award for 18 mos. Minimum intern stipend is $30,000 and partner organization contribution is $18,000
• **PhD students** - $80,000 total research award for 36 mos. Minimum intern stipend is $72,000 (24,000/year) and partner organization contribution is $36,000

**Additional Details**
**Sponsor Deadline:** Ongoing

**Weston Brain Institute: Early Phase Clinical Trials: Canada**
Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. If ignored, the social and economic costs of managing these diseases will continue to rise. Meeting these challenges requires pioneering approaches to accelerating treatments. The Early Phase Clinical Trials: Canada program was created to provide funding support for clinical trials and clinical trial sub-studies that have excellent preliminary data. Eligible Principal Applicants must be at or above the level of Assistant Professor or equivalent, and be affiliated with a Canada Revenue Agency-qualified donee institution located in Canada. Co-applicants and Collaborators must be at the post-doctoral level or above, and can be working outside Canada.

An application requires the submission of a Letter of Intent which will be reviewed by our scientific review committee. Applicants with high potential projects will then be invited to submit a Proposal. Instructions for submitting the Proposal will be forwarded to those invited. Applicants can expect to receive the outcome of their LOI application approximately 2 months after submission.

**Funding Details:** A maximum of $1,500,000 per project over up to 4 years.

**Additional Details**
**Sponsor Deadline:** Ongoing

**Simons Foundation, Simons Foundation Autism Research Initiative (SFARI): SFARI Explorer Award**
This award program is designed to enhance our existing support of autism research by providing timely resources to enable focused experiments highly relevant to our mission. A deeper understanding of the mechanisms underlying autism spectrum disorders or potential therapeutic approaches will require investigation at multiple levels, including but not limited to studies focused on gene discovery, molecular mechanisms, circuits, anatomy, and cognition and behavior. We will consider proposals at all of these levels.

**Funding Details:** SFARI will support applications for maximum of $80,000, including indirect costs, for one year, non-renewable.

**Additional Details**
**Sponsor Deadline:** Ongoing

**OCE Voucher for Innovation and Productivity (VIP I) Program**
The VIP I Program brings industry and academia together to solve industry’s innovation challenges. It helps eligible companies develop, implement and commercialize technical innovations by supporting partnerships between Ontario’s industry and publicly funded post-secondary institutions. The program supports collaborations between industry and post-secondary institutions up to 12 months in duration that lead to knowledge mobilization, commercialization and increased productivity with significant economic impact (i.e. generating new revenues and high-value jobs) for Ontario including the development of new products and/or processes, facilitate productivity improvements. Open to all disciplines, but it has to be a for-profit. Company must have been in operation for a minimum of two years, AND have a minimum of two full-time employees.

**Funding Details:** OCE will support up to 50% of the eligible research costs, to a maximum OCE investment of $20,000.

**Additional Details**
**Sponsor Deadline:** Ongoing

*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

**OCE Voucher for Innovation and Productivity II (VIP II) Program**
The VIP II program helps established Ontario-based companies develop, implement and commercialize technical innovations by supporting partnerships with publicly-funded post-secondary institutions. Projects funded through VIP II address company needs by enabling the development of new products and/or processes, or facilitating productivity improvements, by leveraging post-
secondary institutions' skills and resources. Projects must ultimately help generate new revenues and create high-value jobs for Ontario companies. You can also leverage your sponsor’s contribution through the NSERC CRD program for additional research funds.

**Funding Details:** The VIP II program supports collaborations between companies and publicly-funded post-secondary institutions for durations of 12 and 24 months to a maximum of $150,000

**Additional Details**
**Sponsor Deadline:** Ongoing
*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

---

**TalentEdge Internship Program (TIP)**
Ontario’s TalentEdge Internship Program (TIP) provides support for current college and university students (specifically current graduate students and final year undergraduate students), and recent Masters graduates (within three years of graduation), to work on industry-driven research and development projects. Projects must have a clearly-defined R&D component, where R&D is defined by the discipline and is inclusive of all areas of specialization and disciplines. The TalentEdge Internship Program is open to students and recent graduates from across all disciplines, and all areas of specialization.

**Funding Details:** Each four-month internship is valued at $20,000 as follows: $10,000 contribution from OCE; $5,000 company cash contribution; $5,000 company in-kind contribution. It is possible to also leverage your sponsor’s contribution through the NSERC CRD program for additional research funds.

**Additional Details**
**Sponsor Deadline:** Ongoing
*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

---

**TalentEdge Fellowship Program**
Ontario’s TalentEdge Fellowship Program (TFP) provides support for Ontario-based PhD graduates and post-doctoral fellows to work on industry-driven research and development projects. Companies can tap into world-class talent coming out of Ontario's publicly-funded post-secondary institutions and strengthen their capacity to develop new products, services, and processes.

**Funding Details:** Each 12-month fellowship is valued at $85,000 as follows
- $35,000 contribution from OCE
- $25,000 company cash contribution
- $25,000 company in-kind contribution

**Additional Details**
**Sponsor Deadline:** Ongoing
*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

---

**MITACS Accelerate Program**
Canada’s premiere research internship program provides interns with the opportunity to transfer their skills from theory to real-world application, while companies gain a competitive advantage by accessing high-quality research expertise. Interns spend approximately half their time on-site with the industry partner; the remainder is spent at the university advancing the research under the guidance of a faculty supervisor. Not-for-profit organizations are eligible.

**Funding Details:** Funding starts at $15,000

**Additional Details**
**Sponsor Deadline:** Ongoing
*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

---

**MITACS Globalink Partnership Award**
The Mitacs Globalink Partnership Award supports research collaborations between graduate students at Canadian universities and international industry partners. The award is open to graduate students in all disciplines at Mitacs Full, Associate and Honorary Partner universities and for-profit companies in any country (except the United States).
Funding Details: A $15,000 CAD research grant in the Canadian professor’s name to support student travel and accommodation expenses, research-related expenses, and student stipend.

Additional Details
Sponsor Deadline: Ongoing
*To Apply, Contact Bertha Monrose, Contracts Advisor, MILO at monrose@mcmaster.ca or extension 22416*

Department of Defense Breast Cancer Research Program (BCRP) Funding Opportunities for Fiscal Year 2018
The Department of Defense has released 6 new funding opportunities for their Breast Cancer Research Program. Please see Additional Details link for further information. Please note respective deadlines for each award.

Funding Details:
- **Era of Hope Scholar Award** – Maximum funding of $2.5M for direct and indirect costs for a maximum of 4 years.
- **Breakthrough Award Levels 1 and 2**
  - Funding Level 1 – Maximum funding of $375,000 for direct and indirect costs for a maximum of 3 years.
  - Funding Level 1 with partnering PI Option – Maximum funding of $600,000 for direct and indirect costs for a maximum of 3 years.
  - Funding Level 2 – Maximum funding of $750,000 for direct and indirect costs for a maximum of 3 years.
  - Funding Level 2 with partnering PI Option – Maximum funding of $1M for direct and indirect costs for a maximum of 3 years.
- **Breakthrough Fellowship Award** – Maximum funding of $300,000 for direct and indirect costs for a maximum of 3 years.

LOI Deadline: **May 16, 2018** (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: **May 23, 2018**
Sponsor Deadline: **May 30, 2018**

Funding Details:
- **Innovator Award** – Maximum funding of $5M for direct and indirect costs for a maximum of 4 years.
- **Breakthrough Award Levels 3 and 4**
  - Funding Level 3 – Maximum funding of $2.5M for direct and indirect costs for a maximum of 4 years.
  - Funding Level 3 with partnering PI option – Maximum funding of $4M for direct and indirect costs for a maximum of 4 years.
  - Funding Level 4 and Funding Level 4 with partnering PI option – Maximum funding of $10M for direct and indirect costs for a maximum of 4 years.
- **Distinguished Investigator Award** – Maximum funding of $3M for direct and indirect costs for a maximum of 4 years.

LOI Deadline: **May 15, 2018** (A pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: **July 31, 2018**
Sponsor Deadline: **August 14, 2018**

Department of Defense Ovarian Cancer Research Program (OCRP) Funding Opportunities for Fiscal Year 2018
The Department of Defense has released 5 new funding opportunities for their Ovarian Cancer Research Program. Please see Additional Details link for further information. Please note respective deadlines for each award.

Funding Details:
- **Investigator-Initiated Research Award** – Maximum funding of $450,000 for direct and indirect costs for a maximum of 3 years.
- **Pilot Award** – Maximum funding of $250,000 for direct and indirect costs for a maximum of 2 years.

LOI Deadline: **May 30, 2018** (A Pre-application is required and must be submitted through eBRAP)
Internal HRS Deadline: August 8, 2018  
Sponsor Deadline: August 22, 2018

Funding Details:
- **Clinical Development Award** – Maximum Funding of $600,000 for direct and indirect costs for a maximum of 3 years. Funding is increased to $800,000 for direct costs with a qualified nested Early Career Investigator.
- **Omnics Consortium Development Award** – Maximum funding of $400,000 for direct and indirect costs for a maximum of 2 years.
- **Ovarian Cancer Academy Award** – Early-Career Investigator – Maximum funding of $725,000 for direct and indirect costs for a maximum of 4 years.

LOI Deadline: July 25, 2018 (A Pre-application is required and must be submitted through eBRAP)  
Internal HRS Deadline: August 1, 2018  
Sponsor Deadline: August 8, 2018

**Department of Defense Peer Reviewed Medical Research Program (PRMRP) Funding Opportunities for Fiscal Year 2018**

The Department of Defense has released 4 new funding opportunities for their Ovarian Cancer Research Program. Please see Additional Details link for further information. Please note respective deadlines for each award.

Funding Details:
- **Discovery Award** – Maximum funding of $200,000 for direct costs (plus indirect costs) for a maximum of 18 months

LOI Deadline: June 14, 2018 (A Pre-application is required and must be submitted through eBRAP)  
Internal HRS Deadline: June 21, 2018  
Sponsor Deadline: June 28, 2018

Funding Details:
- **Investigator-initiated Research Award** – Maximum funding of $1.2 million for direct costs (plus indirect costs); $1.5 million for direct costs (plus indirect costs) for applications including a Partnering PI Option Maximum period of performance is 3 years
- **Technology/Therapeutic Development Award** – Maximum funding of $3M for direct costs (plus indirect costs) for a maximum of 3 years

LOI Deadline: June 12, 2018 (A Pre-application is required and must be submitted through eBRAP)  
Internal HRS Deadline: September 6, 2018  
Sponsor Deadline: September 20, 2018

Funding Details:
- **Focused Program Award** – Maximum funding of $10 million for total costs (includes direct and indirect costs) for a maximum of 4 years.

LOI Deadline: June 19, 2018 (A Pre-application is required and must be submitted through eBRAP)  
Internal HRS Deadline: September 6, 2018  
Sponsor Deadline: September 20, 2018

**Department of Defense Amyotrophic Lateral Sclerosis Research Program (ALSRP) Funding Opportunities for Fiscal Year 2018**

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

The mission of the ALSRP is to fund innovative pre-clinical research to develop new treatments for ALS for the benefit of Service members, Veterans, and the general public.
Funding Details:

- **Therapeutic Development Award** – Maximum funding of $1M for direct costs for the standard award. Maximum funding of $1,250,000 for direct costs for submissions under the Therapeutically Relevant Marker Option. Maximum period of performance is 2 years.

- **Therapeutic Idea Award** – Maximum funding of $500,000 for direct costs for a maximum period of performance of 2 years.

Additional Details

LOI Deadline: **June 22, 2018** (A pre-application is required and must be submitted through eBRAP)

Internal HRS Deadline: **September 27, 2018**

Sponsor Deadline: **October 11, 2018**

---

**Department of Defense Bone Marrow Failure Research Program (BMFRP) Funding Opportunities for Fiscal Year 2018**

The objective of the FY18 BMFRP is to fund scientifically meritorious research focused on BMF diseases. Investigator-initiated research is encouraged in the areas of congenital or acquired BMF. Studies focused on BMF diseases and their progressions to other malignancies, such as leukemia, are acceptable. However, research primarily focused on myeloproliferative neoplasms, leukemia, or other malignancies is discouraged. Stem cell biology studies and translational projects including bone marrow transplantation studies should be clearly related to BMF diseases.

**Funding Details:** Maximum funding of $325,000 for direct and indirect costs for a maximum of 2 years.

**Additional Details**

LOI Deadline: **July 16, 2018** (A pre-application is required and must be submitted through eBRAP)

Internal HRS Deadline: **October 18, 2018**

Sponsor Deadline: **November 1, 2018**

---